Advisory Committee on Immunization Practices (ACIP), 4889-4890 [2022-01820]
Download as PDF
<![CDATA[
4889
Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response (in
hours)
Total burden
(in hours)
Form name
Consumers ....................
50
1
20/60
17
50
1
20/60
17
HCPs .............................
HCPs .............................
Be Antibiotics Aware Consumer Pilot Assessment Pretest.
Be Antibiotics Aware Consumer Pilot Assessment Posttest.
HCP Be Antibiotics Aware Campaign Pretest ....
Be Antibiotics Aware Posttest .............................
50
50
1
1
20/60
20/60
17
17
Total ........................
..............................................................................
........................
........................
........................
68
Consumers ....................
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2022–01886 Filed 1–28–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2022–0015]
Advisory Committee on Immunization
Practices (ACIP)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting and request
for comment.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
Centers for Disease Control and
Prevention (CDC) announces the
following meeting of the Advisory
Committee on Immunization Practices
(ACIP). This meeting is open to the
public. Time will be available for public
comment. The meeting will be webcast
live via the World Wide Web.
DATES: The meeting will be held on
February 23–24, 2022, from 10:00 a.m.
to 5:00 p.m., EST (times subject to
change). Written comments must be
received on or before February 24, 2022.
ADDRESSES: You may submit comments
identified by Docket No. CDC–2022–
0015 by either of the following methods:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS H24–8, Atlanta, Georgia 30329–
4027, Attn: ACIP Meeting.
Instructions: All submissions received
must include the Agency name and
Docket Number. All relevant comments
received in conformance with the
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Number of
responses per
respondent
Number of
respondents
Type of respondents
VerDate Sep<11>2014
17:38 Jan 28, 2022
Jkt 256001
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
Written public comments submitted
72 hours prior to the ACIP meeting will
be provided to ACIP members before the
meeting.
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, ACIP Committee
Management Specialist, National Center
for Immunization and Respiratory
Diseases, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS H24–8, Atlanta, Georgia 30329–
4027; Telephone: (404) 639–8367;
Email: ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The committee is charged
with advising the Director, CDC, on the
use of immunizing agents. In addition,
under 42 U.S.C. 1396s, the committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines for Children (VFC) program,
along with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under provisions of the Affordable Care
Act, section 2713 of the Public Health
Service Act, immunization
recommendations of the ACIP that have
been approved by the CDC Director and
appear on CDC immunization schedules
must be covered by applicable health
plans.
Matters To Be Considered: The agenda
will include discussions on, hepatitis B
vaccines, influenza vaccines,
pneumococcal vaccine, cholera vaccine,
human papillomavirus vaccine, MMR
vaccine, respiratory syncytial virus
vaccine, and tickborne encephalitis
vaccine. Recommendation votes on
cholera vaccine and tickborne
encephalitis vaccine are scheduled. No
Vaccines for Children (VFC) votes are
scheduled. Agenda items are subject to
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
change as priorities dictate. For more
information on the meeting agenda visit
https://www.cdc.gov/vaccines/acip/
meetings/meetings-info.html.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: Written
comments must be received on or before
February 24, 2022.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment. Oral
public comment will occur before any
scheduled votes including all votes
relevant to the ACIP’s Affordable Care
Act and Vaccines for Children Program
roles. Priority will be given to
individuals who submit a request to
make an oral public comment before the
meeting according to the procedures
below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the February 23–24,
2022, ACIP meeting must submit a
request at https://www.cdc.gov/vaccines/
E:\FR\FM\31JAN1.SGM
31JAN1
4890
Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices
acip/meetings/ no later than 11:59 p.m.,
EST, February 21, 2022, according to the
instructions provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
by February 22, 2022. To accommodate
the significant interest in participation
in the oral public comment session of
ACIP meetings, each speaker will be
limited to 3 minutes, and each speaker
may only speak once per meeting.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2022–01820 Filed 1–28–22; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–22–22CB; Docket No. CDC–2022–
0011]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
Agencies the opportunity to comment
on a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled Assessment for the Get Ahead of
Sepsis (GAOS) Consumer Campaign.
This assessment collects on-line survey
data from target consumer groups and
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:38 Jan 28, 2022
Jkt 256001
healthcare professionals (HCP) before
and after the campaign.
DATES: CDC must receive written
comments on or before April 1, 2022.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2022–
0011 by either of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329; phone:
404–639–7570; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal Agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
Assessment for the Get Ahead of
Sepsis (GAOS) Consumer Campaign—
New—National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Sepsis is a life threating emergency,
and it is the body’s overactive and toxic
response to an infection. Each year 1.7
million adults in the United States
develop sepsis, with 270,000 fatalities.
Sepsis is the leading cause of death in
hospitals and one out of three hospital
fatalities are due to sepsis infection.
Sepsis management in U.S. hospitals is
the highest when compared to inpatient
cost for all other medical conditions.
Annual costs are estimated to be over
$62 billion.
In media and public health
campaigns, antimicrobial resistance and
sepsis are rarely presented together
which does not make their linkage
apparent. It has been concluded that
sepsis and antimicrobial stewardship
should not be discussed in isolation.
Surprisingly, 24 percent of adults in the
U.S. have never heard of sepsis, so this
presents a unique opportunity for future
messaging campaigns.
The goals of the GAOS educational
campaign are to prevent and reduce
infections that lead to sepsis and to
optimize healthcare quality and patient
safety by raising awareness, knowledge,
and motivating behavior change related
to sepsis prevention, early recognition,
and appropriate treatment among
consumer target audiences. A panel
survey will be utilized to recruit
participants. Surveys will be distributed
to consumer target groups and HCPs
both before and after the media
campaign and partner outreach.
Consumer audiences include:
(1) Cancer patients and their
caregivers (English speaking),
(2) Patients who survived severe
COVID–19 or sepsis and their caregivers
(English speaking),
E:\FR\FM\31JAN1.SGM
31JAN1
]]>Agencies
[Federal Register Volume 87, Number 20 (Monday, January 31, 2022)]
[Notices]
[Pages 4889-4890]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01820]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2022-0015]
Advisory Committee on Immunization Practices (ACIP)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with the Federal Advisory Committee Act, the
Centers for Disease Control and Prevention (CDC) announces the
following meeting of the Advisory Committee on Immunization Practices
(ACIP). This meeting is open to the public. Time will be available for
public comment. The meeting will be webcast live via the World Wide
Web.
DATES: The meeting will be held on February 23-24, 2022, from 10:00
a.m. to 5:00 p.m., EST (times subject to change). Written comments must
be received on or before February 24, 2022.
ADDRESSES: You may submit comments identified by Docket No. CDC-2022-
0015 by either of the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Centers for Disease Control and Prevention, 1600
Clifton Road NE, MS H24-8, Atlanta, Georgia 30329-4027, Attn: ACIP
Meeting.
Instructions: All submissions received must include the Agency name
and Docket Number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
Written public comments submitted 72 hours prior to the ACIP
meeting will be provided to ACIP members before the meeting.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, ACIP Committee
Management Specialist, National Center for Immunization and Respiratory
Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H24-8, Atlanta, Georgia 30329-4027; Telephone: (404) 639-8367;
Email: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The committee is charged with advising the Director, CDC,
on the use of immunizing agents. In addition, under 42 U.S.C. 1396s,
the committee is mandated to establish and periodically review and, as
appropriate, revise the list of vaccines for administration to vaccine-
eligible children through the Vaccines for Children (VFC) program,
along with schedules regarding dosing interval, dosage, and
contraindications to administration of vaccines. Further, under
provisions of the Affordable Care Act, section 2713 of the Public
Health Service Act, immunization recommendations of the ACIP that have
been approved by the CDC Director and appear on CDC immunization
schedules must be covered by applicable health plans.
Matters To Be Considered: The agenda will include discussions on,
hepatitis B vaccines, influenza vaccines, pneumococcal vaccine, cholera
vaccine, human papillomavirus vaccine, MMR vaccine, respiratory
syncytial virus vaccine, and tickborne encephalitis vaccine.
Recommendation votes on cholera vaccine and tickborne encephalitis
vaccine are scheduled. No Vaccines for Children (VFC) votes are
scheduled. Agenda items are subject to change as priorities dictate.
For more information on the meeting agenda visit https://www.cdc.gov/vaccines/acip/meetings/meetings-info.html.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket.
Written Public Comment: Written comments must be received on or
before February 24, 2022.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Oral public comment will occur
before any scheduled votes including all votes relevant to the ACIP's
Affordable Care Act and Vaccines for Children Program roles. Priority
will be given to individuals who submit a request to make an oral
public comment before the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the February 23-24, 2022, ACIP meeting must
submit a request at https://www.cdc.gov/vaccines/
[[Page 4890]]
acip/meetings/ no later than 11:59 p.m., EST, February 21, 2022,
according to the instructions provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email by February 22, 2022. To accommodate the significant
interest in participation in the oral public comment session of ACIP
meetings, each speaker will be limited to 3 minutes, and each speaker
may only speak once per meeting.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2022-01820 Filed 1-28-22; 8:45 am]
BILLING CODE 4163-18-P
